• Year-on-year, leading companies
    trust GBI Research's clinical & competitive research
Who We Help
Pharma-Biotech
You are here:
Who we help >
Pharma-Biotech

Pharma-Biotech

Year-on-year, leading pharma and biotech companies trust GBI Research’s clinical data and analysis as an important input into strategic planning processes. Our content is particularly relevant to R&D, business development, licensing and strategic roles.

GBI Research’s product set covers both major indications and more niche disease areas characterized by a high degree of innovation:

  • Extensive analysis of current treatment landscapes and algorithms

  • Comprehensive examination and distillation of clinical data and academic research

  • Exhaustive analysis of industry-leading proprietary databases containing pipeline and marketed products, clinical trials, patents and deals data

  • Application of novel analytical frameworks and methodologies to identify and highlight opportunities

  • Compelling and usable data benchmarks to support strategic decision making

  • Intuitive report formats communicating key insights and findings contextualized against the broader industry landscape

  • Identification of unique, novel, and potentially transformative development programs

  • An evidence-based. scientific and clinical perspective about the rationale, strength and weakness of novel products

Analyst Views

28 Nov 16
Repurposing Type 2 Diabetes Mellitus Drugs for Alzheimer’s ....
In this Analyst View, Fiona Chisholm, Analyst for GBI Research, discusses the potential f.....
Read post
21 Nov 16
Urological Cancer Treatment Landscape to be Transformed by ....
In this Analyst View, Adam Bradbury, Associate Analyst for GBI Research, discuses current.....
Read post

White Papers

22 Nov 16
An Exploration of Novel and Repositioned Calcium Transport ....
This whitepaper discusses the increasing interest in using repositioned calcium transport....
Read post
14 Nov 16
The Emerging Field of Cannabinoid-Based Products....
This white paper discusses the current commercial landscape for cannabinoid-based product....
Read post

Press Releases

15 Feb 17
Immunology attracting high level of investment as companies....
With a total of 2,145 products currently in development, the immunology market is experie.....
Read post
14 Feb 17
Roche to gain most as Biogen remains leader in neurodegener....
Roche will be the biggest mover in the neurodegenerative drugs space over the next five y.....
Read post